Evidence map›Paper›PMID 35207403›Full record

ReviewJournal of clinical medicine2022

Acetylcholine Use in Modern Cardiac Catheterization Laboratories: A Systematic Review.

Andrea Marrone, Rita Pavasini, Ennio Scollo, Federico Gibiino, Graziella Pompei, Serena Caglioni, Simone Biscaglia, Gianluca Campo, Matteo Tebaldi

Open access · goldAbstract readReview
In one paragraph

Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Contemporary Antianginal Therapy.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026
    Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Andrea MarroneCardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, 44124 Cona, FE, Italy.ORCID 0000-0002-4408-0271
Rita PavasiniCardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, 44124 Cona, FE, Italy.ORCID 0000-0002-1763-9711
Ennio ScolloCardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, 44124 Cona, FE, Italy.
Federico GibiinoCardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, 44124 Cona, FE, Italy.ORCID 0000-0002-4451-4148
Graziella PompeiCardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, 44124 Cona, FE, Italy.
Serena CaglioniCardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, 44124 Cona, FE, Italy.
Simone BiscagliaCardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, 44124 Cona, FE, Italy.ORCID 0000-0001-6074-2370
Gianluca CampoCardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, 44124 Cona, FE, Italy.ORCID 0000-0002-5150-188X
Matteo TebaldiCardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, 44124 Cona, FE, Italy.ORCID 0000-0002-2805-8090

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe use of acetylcholine for the diagnosis of vasospastic angina is recommended by international guidelines. However, its intracoronary use is still off-label due to the absence of safety studies. We aimed to perform a systematic review of the literature to identify adverse events related to the intracoronary administration of acetylcholine for vasoreactivity testing to fill this gap. METHODS AND

resultsWe conducted a systematic review of observational studies and randomized controlled trials dealing with the intracoronary administration of acetylcholine. Articles were searched in MEDLINE (PubMed) using the MeSH strategy. Three independent reviewers determined whether the studies met the inclusion and exclusion criteria. A total of 434 articles were selected. Data concerning clinical characteristics, study population, acetylcholine dosage, and adverse effects were retrieved from the articles. Overall, 71,566 patients were included, of which only 382 (0.5%) developed one adverse event, and there were no fatal events reported (0%).

conclusionsIntracoronary administration of acetylcholine in the setting of coronary spasm provocation testing is safe and plays a central role in the evaluation of coronary vasomotion disorders, making it worthy of becoming a part of clinical practice in all cardiac catheterization laboratories.

Indexed as

acetylcholine provocation testcoronary spasmdiffuse spasmprognosissafetyvasospastic angina

Identifiers

PMID35207403
PMCPMC8880288
OpenAlexW4213374966

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.